Cyxone AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.01.21	Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod (PR Newswire)
15.01.21	Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod (PR Newswire)
15.12.20	Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA (PR Newswire)
15.12.20	Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA (PR Newswire)
08.12.20	Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients (PR Newswire)
08.12.20	Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients (PR Newswire)
11.11.20	The board of directors of Cyxone have decided to carry out a directed issue of units of approximately SEK 19 million and an issue of warrants to current shareholders (PR Newswire)
10.11.20	Cyxone files patent application to extend exclusivity of Rabeximod (PR Newswire)
10.11.20	Cyxone files patent application to extend exclusivity of Rabeximod (PR Newswire)
25.09.20	Cyxone revises the development plan for Rabeximod (PR Newswire)
25.09.20	Cyxone revises the development plan for Rabeximod (PR Newswire)
14.09.20	Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients (PR Newswire)
14.09.20	Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients (PR Newswire)
08.07.20	Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor (PR Newswire)
08.07.20	Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor (PR Newswire)
06.07.20	Cyxone Signs Agreement With Dr Maarten Kraan as Senior Scientific Advisor (PR Newswire)
06.07.20	Cyxone Signs Agreement With Dr Maarten Kraan as Senior Scientific Advisor (PR Newswire)
10.06.20	Cyxone Enters Development Agreement with Inventor Kalev Kask (PR Newswire)
10.06.20	Cyxone Enters Development Agreement with Inventor Kalev Kask (PR Newswire)
10.06.20	Cyxone Files New Patent Applications Following Additional Innovation Achievements (PR Newswire)
10.06.20	Cyxone Files New Patent Applications Following Additional Innovation Achievements (PR Newswire)
20.05.20	Dr Tara Heitner Appointed New CEO for Cyxone (PR Newswire)
20.05.20	Dr Tara Heitner Appointed New CEO for Cyxone (PR Newswire)
29.01.20	Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program (PR Newswire)
29.01.20	Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program (PR Newswire)
21.11.19	Cyxone Signs a UK Contract Research Organization for Six-month Toxicology Studies With Rabeximod (PR Newswire)
21.11.19	Cyxone Signs a UK Contract Research Organization for Six-month Toxicology Studies With Rabeximod (PR Newswire)
13.11.19	Kjell G. Stenberg Steps Down as CEO of Cyxone (PR Newswire)
13.11.19	Kjell G. Stenberg Steps Down as CEO of Cyxone (PR Newswire)
06.09.19	First Berlin Equity Research Publishes Independent Analysis of Cyxone (PR Newswire)
04.09.19	Cyxone Explores Orphan Drug Designation for Rabeximod (PR Newswire)
04.09.19	Cyxone Explores Orphan Drug Designation for Rabeximod (PR Newswire)
29.08.19	Cyxone's CEO Kjell G. Stenberg Acquires Additional Shares in the Company (PR Newswire)
02.08.19	Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial (PR Newswire)
02.08.19	Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial (PR Newswire)
19.07.19	Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc. (PR Newswire)
19.07.19	Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc. (PR Newswire)
12.07.19	Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial (PR Newswire)
12.07.19	Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial (PR Newswire)
05.07.19	Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod (PR Newswire)
05.07.19	Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod (PR Newswire)
01.07.19	First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone (PR Newswire)
20.06.19	Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS (PR Newswire)
20.06.19	Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS (PR Newswire)
23.05.19	Cyxone Submits Application to Start First-in-human Trial With T20K in MS (PR Newswire)
23.05.19	Cyxone Submits Application to Start First-in-human Trial With T20K in MS (PR Newswire)
20.03.19	Cyxone Announces Strategic Intent to Position its Drug Candidate T20K in MS as a Prophylactic Agent (PR Newswire)
04.02.19	Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS (PR Newswire)
04.02.19	Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS (PR Newswire)
03.12.18	First Berlin Equity Research Publishes Updated Independent Analysis of Cyxone (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	73.48	1.63 %	K V
CieFinRichemont	128.80	0.90 %	K V
Alcon	77.76	0.83 %	K V
Part Grp Hldg	1’310.00	0.81 %	K V
Sika	237.70	0.81 %	K V
Swiss Life Hldg	687.20	-0.46 %	K V
Zurich Insur Gr	558.20	-0.46 %	K V
Kuehne+Nagel Int	211.90	-0.70 %	K V
Givaudan	3’862.00	-1.18 %	K V
Novartis	91.14	-2.02 %	K V

Nachrichten zu Cyxone AB

Aktien Top/Flop

Meistgelesene Nachrichten